News Sentiment

AVBP sentiment intelligence

ArriVent BioPharma, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 66 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 33.19 Week of 17 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 58

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend active

-1.5% over one week, +4.6% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

ArriVent BioPharma Q1 2026 Earnings: EPS Miss Reflects Increased R&D Spending; Shares Edge Higher - Quarterly Financial Update

Market Reaction

Balanced read

65/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction -1.5% Price digesting
Trend fit Trend active 4.6% over four weeks
Fair value 44.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 43
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 58
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
TradingView 12
Stock Titan 5
dars.gov.et 4
TradingKey 4
Moomoo 3
simplywall.st 3
Seeking Alpha 3

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 27
Analyst action 4
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 66
Stock Traders Daily Direct company coverage

(AVBP) Volatility Zones as Tactical Triggers

This article analyzes Arrivent Biopharma Inc. (NASDAQ: AVBP) using AI models to provide tactical trading triggers. It identifies weak near-term sentiment but strong mid and long-term outlooks, outlining specific entry, target, and stop-loss zones for position, momentum, and risk-

Tone
Neutral 50/100
Event
Analyst action
Published
12 Jul 2026 09:40
Source
Stock Traders Daily
TradingView Direct company coverage

ArriVent BioPharma, Inc. Financial Disclosures & SEC Filings

This page provides a comprehensive overview of ArriVent BioPharma, Inc.'s financial disclosures and SEC filings, including annual reports (10-K), quarterly reports (10-Q), and earnings releases (8-K). It details key corporate events, earnings summaries, and pipeline progress from

Tone
Positive 64/100
Event
Earnings
Published
01 Jul 2026 21:11
Source
TradingView
TradingView Direct company coverage

Number of shareholders of ArriVent BioPharma, Inc. – NASDAQ:AVBP

This article provides financial information for ArriVent BioPharma, Inc. (NASDAQ: AVBP), specifically focusing on the number of shareholders. It indicates that the company's market is closed with no trades and lists various data providers for its financial and reference data. The

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 23:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP

This article focuses on the enterprise value to revenue forward metric for ArriVent BioPharma, Inc. (NASDAQ: AVBP). It highlights the financial data available on TradingView for this specific pharmaceutical company. The content appears to be a financial data point from a larger p

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 00:40
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP

The article focuses on the price-to-earnings forward metric for ArriVent BioPharma, Inc. (NASDAQ: AVBP). It provides navigation and structural elements typical for a financial data platform, indicating where users can find financials, news, community, and technical analysis for t

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 20:10
Source
TradingView
TradingView Direct company coverage

Price to book forward of ArriVent BioPharma, Inc. – BOATS:AVBP

This page provides financial information for ArriVent BioPharma, Inc. (AVBP) on the Blue Ocean Alternative Trade System (BOATS). It specifically highlights the "Price to book forward" metric for the company. The content also details various features and services offered by Tradin

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 20:10
Source
TradingView
TradingView Direct company coverage

Number of shareholders of ArriVent BioPharma, Inc. – BOATS:AVBP

This article focuses on the number of shareholders for ArriVent BioPharma, Inc. (AVBP), referencing data from the Blue Ocean Alternative Trade System (BOATS) via TradingView. The content primarily displays navigation and boilerplate information typical of a financial data platfor

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 19:09
Source
TradingView
TradingView Direct company coverage

Price to book forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP

This page from TradingView displays the "Price to book forward" financial metric for ArriVent BioPharma, Inc. (NASDAQ:AVBP). It indicates that the market was closed at the time of access with no trades occurring. The content is primarily a data placeholder within a financial plat

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 13:41
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of ArriVent BioPharma, Inc. – BOATS:AVBP

This article provides financial information for ArriVent BioPharma, Inc. (AVBP) with a focus on its price-to-earnings forward metric. The content highlights the company's financials, news, and market data available through the TradingView platform. It appears to be a financial da

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 08:41
Source
TradingView
TradingView Direct company coverage

AVBP Forecast — Price Target — Prediction for 2027

The article provides a forecast for ArriVent BioPharma, Inc. (AVBP) stock, including a 1-year price target of $43.92 based on 12 analysts. It details current stock performance, historical highs and lows, volatility, market capitalization, and upcoming earnings information. The an

Tone
Positive 71/100
Event
Earnings
Published
26 Jun 2026 06:40
Source
TradingView
TradingView Direct company coverage

ArriVent BioPharma, Inc. Actuals & Estimates (NASDAQ:AVBP)

This article provides an overview of ArriVent BioPharma, Inc. (NASDAQ:AVBP), presenting its current stock price, historical performance, and analyst forecasts. It includes key financial metrics like market capitalization, earnings per share, and revenue, alongside details on vola

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 00:12
Source
TradingView
Stock Titan Direct company coverage

ArriVent BioPharma (AVBP) director receives 13,562 stock options at $31.74

ArriVent BioPharma director Chris Nolet was granted 13,562 non-qualified stock options with an exercise price of $31.74 per share. These options are set to expire on June 17, 2036, and the underlying shares will vest on June 18, 2027, contingent on his continued service. The tran

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 06:09
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Arrivent Biopharma Inc stock hits 52-week high at 33.65 USD

Arrivent Biopharma Inc (AVBP) stock reached a 52-week high of $33.62, currently trading at $33.14. Despite this achievement, InvestingPro analysis suggests the stock is overvalued. The company recently filed for a $250 million at-the-market equity offering, and Cantor Fitzgerald

Tone
Positive 69/100
Event
Market update
Published
23 Jun 2026 05:40
Source
Investing.com Nigeria
Stock Titan Direct company coverage

ArriVent BioPharma (AVBP) director receives grant of 13,562 stock options at $31.74

ArriVent BioPharma, Inc. (AVBP) director John Hohneker was granted 13,562 non-qualified stock options with an exercise price of $31.74 per share. These options, which expire on June 17, 2036, will vest on the first anniversary of the June 18, 2026 grant date, contingent on Hohnek

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 05:40
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 4 Arrivent Biopharma Inc For: 22 June By Investing.com

This article from Investing.com reports on a Form 4 filing for Arrivent Biopharma Inc pertaining to June 22. It mentions the stock symbol AVBP and its percentage change. The article itself is very brief and acts more as an announcement of the filing rather than an analysis.

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 04:11
Source
Investing.com Nigeria
Stock Titan Direct company coverage

ArriVent BioPharma (AVBP) director receives grant of 13,562 stock options

ArriVent BioPharma director Kristine Peterson was granted 13,562 non-qualified stock options at an exercise price of $31.74 per share. These options will vest on the first anniversary of the grant date, provided she continues her service, and are set to expire on June 17, 2036. T

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 02:10
Source
Stock Titan
Stock Titan Direct company coverage

ArriVent BioPharma (AVBP) director receives 13,562 stock options grant

ArriVent BioPharma (AVBP) director Parsey Merdad was granted 13,562 non-qualified stock options at an exercise price of $31.74 per share, expiring on June 17, 2036. The options vest on the first anniversary of the June 18, 2026, grant date, contingent on Merdad's continued servic

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 02:10
Source
Stock Titan
Stock Titan Direct company coverage

ArriVent BioPharma (NASDAQ: AVBP) 2026 meeting backs board, auditor

ArriVent BioPharma, Inc. announced the results of its 2026 annual meeting, where stockholders re-elected three Class II directors—James Healy, John Hohneker, and Stuart Lutzker—to serve until the 2029 annual meeting. Stockholders also ratified PricewaterhouseCoopers LLP as the in

Tone
Neutral 50/100
Event
Earnings
Published
22 Jun 2026 20:10
Source
Stock Titan
Simply Wall Street Direct company coverage

ArriVent BioPharma (Nasdaq:AVBP) - Stock Analysis

ArriVent BioPharma (AVBP) is a clinical-stage biopharmaceutical company focused on developing cancer treatments. The company's stock is currently trading significantly below its estimated fair value, with analysts projecting a 37.5% price increase and strong revenue growth. Recen

Tone
Positive 66/100
Event
Earnings
Published
22 Jun 2026 05:40
Source
Simply Wall Street
Stock Traders Daily Direct company coverage

(AVBP) Price Dynamics and Execution-Aware Positioning

This article provides an AI-driven analysis of Arrivent Biopharma Inc. (NASDAQ: AVBP), indicating a near-term neutral sentiment amidst mid and long-term strength. It highlights a lack of resistance above the current price, suggesting upside potential. The analysis also details th

Tone
Positive 67/100
Event
Market update
Published
20 Jun 2026 07:36
Source
Stock Traders Daily